Neuraptive Therapeutics

Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment

WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …

Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More

Aclaris Therapeutics

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More
Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More


Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More